The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
Abstract Background Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5287-z |
| _version_ | 1818036743441481728 |
|---|---|
| author | Amélie Darlix Christophe Hirtz Simon Thezenas Aleksandra Maceski Audrey Gabelle Evelyne Lopez-Crapez Hélène De Forges Nelly Firmin Séverine Guiu William Jacot Sylvain Lehmann |
| author_facet | Amélie Darlix Christophe Hirtz Simon Thezenas Aleksandra Maceski Audrey Gabelle Evelyne Lopez-Crapez Hélène De Forges Nelly Firmin Séverine Guiu William Jacot Sylvain Lehmann |
| author_sort | Amélie Darlix |
| collection | DOAJ |
| description | Abstract Background Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM). Methods 244 MBC patients treated at our institution (2007–2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15–3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM. Results With a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4–20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort. Conclusions Tau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings. |
| first_indexed | 2024-12-10T07:15:48Z |
| format | Article |
| id | doaj.art-81766dec217f436d9f367b46d17020b0 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-10T07:15:48Z |
| publishDate | 2019-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-81766dec217f436d9f367b46d17020b02022-12-22T01:57:56ZengBMCBMC Cancer1471-24072019-01-0119111310.1186/s12885-019-5287-zThe prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastasesAmélie Darlix0Christophe Hirtz1Simon Thezenas2Aleksandra Maceski3Audrey Gabelle4Evelyne Lopez-Crapez5Hélène De Forges6Nelly Firmin7Séverine Guiu8William Jacot9Sylvain Lehmann10Department of Medical Oncology, Institut du Cancer de Montpellier, University of MontpellierLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine – Biotherapy IRMB, CHU Montpellier, INSERMBiometrics Unit, Institut du Cancer de Montpellier, University of MontpellierLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine – Biotherapy IRMB, CHU Montpellier, INSERMMemory Resources and Research Center, University of Montpellier MUSE, CHU MontpellierTranslational Research Unit, Institut du Cancer de Montpellier, University of MontpellierClinical Research Unit, Institut Régional du Cancer de Montpellier, University of MontpellierDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of MontpellierDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of MontpellierDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of MontpellierLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine – Biotherapy IRMB, CHU Montpellier, INSERMAbstract Background Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM). Methods 244 MBC patients treated at our institution (2007–2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15–3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM. Results With a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4–20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort. Conclusions Tau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.http://link.springer.com/article/10.1186/s12885-019-5287-zTau proteinBreast cancerBrain metastasesTumor markersPredictive factorsPrognostic factors |
| spellingShingle | Amélie Darlix Christophe Hirtz Simon Thezenas Aleksandra Maceski Audrey Gabelle Evelyne Lopez-Crapez Hélène De Forges Nelly Firmin Séverine Guiu William Jacot Sylvain Lehmann The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases BMC Cancer Tau protein Breast cancer Brain metastases Tumor markers Predictive factors Prognostic factors |
| title | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| title_full | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| title_fullStr | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| title_full_unstemmed | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| title_short | The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| title_sort | prognostic value of the tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases |
| topic | Tau protein Breast cancer Brain metastases Tumor markers Predictive factors Prognostic factors |
| url | http://link.springer.com/article/10.1186/s12885-019-5287-z |
| work_keys_str_mv | AT ameliedarlix theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT christophehirtz theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT simonthezenas theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT aleksandramaceski theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT audreygabelle theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT evelynelopezcrapez theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT helenedeforges theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT nellyfirmin theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT severineguiu theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT williamjacot theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT sylvainlehmann theprognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT ameliedarlix prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT christophehirtz prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT simonthezenas prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT aleksandramaceski prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT audreygabelle prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT evelynelopezcrapez prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT helenedeforges prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT nellyfirmin prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT severineguiu prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT williamjacot prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases AT sylvainlehmann prognosticvalueofthetauproteinserumlevelinmetastaticbreastcancerpatientsanditscorrelationwithbrainmetastases |